Literature DB >> 12115316

Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma.

Hiroshi Igarashi1, Mariko Esumi, Hajime Ishida, Kiyoki Okada.   

Abstract

BACKGROUND: A high frequency of genetic alterations of the von Hippel-Lindau (VHL) gene and overexpression of the vascular endothelial growth factor (VEGF) gene have been observed independently in human sporadic renal cell carcinoma (RCCs), but to the authors' knowledge the association between the two has not been characterized in primary sporadic RCC. In the current study the authors report the simultaneous comparison of the biallelic inactivation status of the VHL gene and VEGF expression levels in patients with sporadic RCC.
METHODS: DNA and RNA were extracted from 27 sporadic RCC samples. Mutation was analyzed by direct sequencing of the amplified VHL DNA and cDNA. Loss of heterozygosity (LOH) of the gene was analyzed at three polymorphic markers. The VEGF mRNA was measured using Northern blot analysis.
RESULTS: Mutations of the VHL gene were found in 14 of 27 RCC samples (51.9%). LOH analysis by a VHL-intragenic polymorphic marker and 2 extragenic microsatellite markers, D3S1560 and D3S1317, showed that LOH occurred in 10 of 15 RCC samples (66.7%). Overexpression of VEGF mRNA was observed in 17 of 27 RCC cases (63.0%): 15 of the 18 RCC samples estimated to have at least 1 hit, but only 2 of the 6 RCC samples with 0-1 hit, and none of the 3 RCC samples in which the VHL gene was not inactivated.
CONCLUSIONS: VEGF overexpression was found to be correlated with both monoallelic and biallelic VHL inactivation. Alteration of the VHL gene is believed to cause angiogenesis in RCC cases through the overexpression of VEGF. Copyright 2002 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12115316     DOI: 10.1002/cncr.10635

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  17 in total

1.  Knockdown of VEGF receptor-1 (VEGFR-1) impairs macrophage infiltration, angiogenesis and growth of clear cell renal cell carcinoma (CRCC).

Authors:  Chenghai Li; Bin Liu; Zonghan Dai; Yunxia Tao
Journal:  Cancer Biol Ther       Date:  2011-11-15       Impact factor: 4.742

2.  VHL and HIF-1α: gene variations and prognosis in early-stage clear cell renal cell carcinoma.

Authors:  Francesca Lessi; Chiara Maria Mazzanti; Sara Tomei; Claudio Di Cristofano; Andrea Minervini; Michele Menicagli; Alessandro Apollo; Lorenzo Masieri; Paola Collecchi; Riccardo Minervini; Marco Carini; Generoso Bevilacqua
Journal:  Med Oncol       Date:  2014-01-21       Impact factor: 3.064

3.  Improving patient selection for adjuvant therapy in high-risk renal cell carcinoma.

Authors:  Dylan M Buller; Benjamin T Ristau
Journal:  Ann Transl Med       Date:  2019-07

4.  Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma.

Authors:  Alison C Young; Rachel A Craven; Dena Cohen; Claire Taylor; Christopher Booth; Patricia Harnden; David A Cairns; Dewi Astuti; Walter Gregory; Eamonn R Maher; Margaret A Knowles; Adrian Joyce; Peter J Selby; Rosamonde E Banks
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

Review 5.  Molecular basis for the treatment of renal cell carcinoma.

Authors:  Cristina Suárez; Rafael Morales; Eva Muñoz; Jordi Rodón; Claudia M Valverde; Joan Carles
Journal:  Clin Transl Oncol       Date:  2010-01       Impact factor: 3.405

6.  Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317.

Authors:  Michael S Gordon; Michael Hussey; Raymond B Nagle; Primo N Lara; Philip C Mack; Janice Dutcher; Wolfram Samlowski; Joseph I Clark; David I Quinn; Chong-Xian Pan; David Crawford
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

7.  Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect.

Authors:  Emely Castro-Rivera; Sophia Ran; Philip Thorpe; John D Minna
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-23       Impact factor: 11.205

Review 8.  The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.

Authors:  Alyssa Fischer; Shenhong Wu; Alan L Ho; Mario E Lacouture
Journal:  Invest New Drugs       Date:  2013-01-24       Impact factor: 3.850

Review 9.  VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment.

Authors:  W Kimryn Rathmell; Shufen Chen
Journal:  Expert Rev Anticancer Ther       Date:  2008-01       Impact factor: 4.512

10.  Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma.

Authors:  J-J Patard; N Rioux-Leclercq; D Masson; S Zerrouki; F Jouan; N Collet; C Dubourg; B Lobel; M Denis; P Fergelot
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.